CD105 (Endoglin) Expression as a Prognostic Marker in Aggressive Papillary Thyroid Carcinoma
Authors' conclusion
This study supports the potential use of CD105 expression and its quantitative indicator, the CD105 MVD score, as biomarkers for distinguishing benign thyroid nodules from malignant ones and for evaluating the prognosis of PTC.
Study context
- Population
- Patients with benign thyroid nodules, non-metastatic papillary thyroid carcinoma (PTC), and PTC with lymph node metastasis; thyroid tissues analysed for CD105 expression
- Participants
- 148 patients
- Exposure
- CD105 expression and microvascular density (MVD) score in thyroid follicular nodular disease (TFND) vs lymph node metastasis (LNM)(-) PTC vs LNM(+) PTC
- TFNDn = 49reference
- LNM(-) PTCn = 48
- LNM(+) PTCn = 51
- Outcome
- CD105 expression rate
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| CD105 MVD score (Weidner method) | P < 0.001 |
- CD105 MVD score (Weidner method): significantly higher in LNM(+) PTC, unifocal and multifocal LNM(+) PTC, in favour of metastasis
Distant organ metastasis
- CD105 expression detected in all patients with distant organ metastasis; significantly higher MVD scores
- P < 0.001
Original publication
CD105 (Endoglin) Expression as a Prognostic Marker in Aggressive Papillary Thyroid Carcinoma. Clin Endocrinol (Oxf). Published 8 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →